Stock Comparison

JNJ vs PLRZ

Johnson & Johnson vs Polyrizon Ltd

The Verdict

PLRZ takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

PLRZ

Polyrizon Ltd

1.4

out of 10

Distressed

Head-to-Head

$557.1B

Market Cap

$27M

26.5

P/E Ratio

7.3

21.8%

Profit Margin

N/A

26.3%

Return on Equity

-17.8%

0.6

Debt-to-Equity

N/A

Conservative

Overall Risk

Aggressive

1.0

DVR Score

1.4

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

PLRZ1.4/10

Polyrizon Ltd. (PLRZ) has undergone a significant shift from a seemingly defunct entity to an active, albeit extremely high-risk, development-stage biotech. The initiation of its first Clinical Trial Agreement for NASARIX™ (PL-14) Allergy Blocker and recent patent filings demonstrate verifiable operational progress and a strategic vision for capturing a large potential market (nasal barrier techno...

Full PLRZ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.